antibody

Sheep anti Mouse Factor IX

MBS316617

1 mg

500 USD

polyclonal

sheep

nonconjugated

human, mouse

western blot, ELISA, enzyme immunoassay

Antibody

Sheep anti Mouse Factor IX

Factor IX

Sheep Antibody to Mouse Factor IX

factor IX; Coagulation factor IX; coagulation factor IX; FIX F9; factor 9; Christmas factor; OTTHUMP00000024154; plasma thromboplastic component; plasma thromboplastin component; coagulation factor IX; Christmas factor; Plasma thromboplastin component

F9; F9; FIX; P19; PTC; HEMB; MGC129641; MGC129642

FA9_HUMAN

Polyclonal

Sheep

Mouse

Factor IX. Recognizes Mouse Factor IX and Mouse Factor IX alpha.

Protein G chromatography

Purified, Liquid

1mg/ml (OD280nm, E^0.1% = 1.36)

Upon receipt, store at -70 degree C. Avoid multiple freeze/thaw cycles.

EIA/ELISA, Western Blot

Immunogen: Mouse Factor IX

Buffer: 0.05M Sodium phosphate, pH 6.6 containing 0.1M Sodium chloride and 1mM EDTA. Preservative: No. Important Note: Centrifuge before opening to ensure complete recovery of vial contents.

Polyclonal Antibodies to Platelets and Hemostasis Antigens

182609

P00740

51,778 Da

Blood Clotting Cascade Pathway (198840); Complement And Coagulation Cascades Pathway (198880); Complement And Coagulation Cascades Pathway (83073); Complement And Coagulation Cascades Pathway (484); Extrinsic Pathway (106058); Formation Of Fibrin Clot (Clotting Cascade) Pathway (106057); Gamma-carboxylation Of Protein Precursors Pathway (106233); Gamma-carboxylation, Transport, And Amino-terminal Cleavage Of Proteins Pathway (106232); Hemostasis Pathway (106028); Intrinsic Pathway (106059)

This gene encodes vitamin K-dependent coagulation factor IX that circulates in the blood as an inactive zymogen. This factor is converted to an active form by factor XIa, which excises the activation peptide and thus generates a heavy chain and a light chain held together by one or more disulfide bonds. The role of this activated factor IX in the blood coagulation cascade is to activate factor X to its active form through interactions with Ca+2 ions, membrane phospholipids, and factor VIII. Alterations of this gene, including point mutations, insertions and deletions, cause factor IX deficiency, which is a recessive X-linked disorder, also called hemophilia B or Christmas disease. [provided by RefSeq]

Function: Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca2+ ions, phospholipids, and factor VIIIa. Catalytic activity: Selective cleavage of Arg- -Ile bond in factor X to form factor Xa. Subunit structure: Heterodimer of a light chain and a heavy chain; disulfide-linked. Subcellular location: Secreted. Tissue specificity: Synthesized primarily in the liver and secreted in plasma. Domain: Calcium binds to the gamma-carboxyglutamic acid (Gla) residues and, with stronger affinity, to another site, beyond the Gla domain. Post-translational modification: Activated by factor XIa, which excises the activation peptide.The iron and 2-oxoglutarate dependent 3-hydroxylation of aspartate and asparagine is (R) stereospecific within EGF domains. Involvement in disease: Defects in F9 are the cause of recessive X-linked hemophilia B (HEMB) [. MIM:306900]; also known as Christmas disease. Ref.11 Ref.13 Ref.34 Ref.37 Ref.38 Ref.39 Ref.40 Ref.41 Ref.42 Ref.43 Ref.44 Ref.45 Ref.46 Ref.47 Ref.48 Ref.49 Ref.50 Ref.51 Ref.52 Ref.53 Ref.54 Ref.55 Ref.56 Ref.57 Ref.58 Ref.59 Ref.60 Ref.62 Ref.63 Ref.64 Ref.65 Ref.66 Ref.67 Ref.70 Ref.71 Ref.72Note=Mutations in position 43 (Oxford-3, San Dimas) and 46 (Cambridge) prevents cleavage of the propeptide, mutation in position 93 (Alabama) probably fails to bind to cell membranes, mutation in position 191 (Chapel-Hill) or in position 226 (Nagoya OR Hilo) prevent cleavage of the activation peptide.Defects in F9 are the cause of thrombophilia due to factor IX defect (THR-FIX) [. MIM:300807]. A hemostatic disorder characterized by a tendency to thrombosis. Ref.73. Pharmaceutical use: Available under the name BeneFix (Baxter and American Home Products). Used to treat hemophilia B. Miscellaneous: In 1952, one of the earliest researchers of the disease, Dr. R.G. Macfarlane used the patient's surname, Christmas, to refer to the disease and also to refer to the clotting factor which he called the 'Christmas Factor' At the time Stephen Christmas was a 5-year-old boy. He died in 1993 at the age of 46 from acquired immunodeficiency syndrome contracted through treatment with blood products. Sequence similarities: Belongs to the peptidase S1 family.Contains 2 EGF-like domains.Contains 1 Gla (gamma-carboxy-glutamate) domain.Contains 1 peptidase S1 domain.

1 mg

500 USD